- Home
- PLSE vs AUPH Comparison
PLSE vs AUPH Comparison
Compare PLSE & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLSE
- AUPH
- Stock Information
- Founded
- PLSE 2014
- AUPH 1993
- Country
- PLSE United States
- AUPH Canada
- Employees
- PLSE N/A
- AUPH N/A
- Industry
- PLSE Medical/Dental Instruments
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- PLSE Health Care
- AUPH Health Care
- Exchange
- PLSE Nasdaq
- AUPH Nasdaq
- Market Cap
- PLSE 1.1B
- AUPH 1.1B
- IPO Year
- PLSE 2016
- AUPH 1999
- Fundamental
- Price
- PLSE $15.25
- AUPH $8.96
- Analyst Decision
- PLSE Buy
- AUPH Strong Buy
- Analyst Count
- PLSE 1
- AUPH 2
- Target Price
- PLSE $22.00
- AUPH $11.50
- AVG Volume (30 Days)
- PLSE 188.3K
- AUPH 2.0M
- Earning Date
- PLSE 08-11-2025
- AUPH 07-31-2025
- Dividend Yield
- PLSE N/A
- AUPH N/A
- EPS Growth
- PLSE N/A
- AUPH N/A
- EPS
- PLSE N/A
- AUPH 0.27
- Revenue
- PLSE N/A
- AUPH $247,295,000.00
- Revenue This Year
- PLSE N/A
- AUPH $12.15
- Revenue Next Year
- PLSE $700.00
- AUPH $18.34
- P/E Ratio
- PLSE N/A
- AUPH $33.62
- Revenue Growth
- PLSE N/A
- AUPH 29.20
- 52 Week Low
- PLSE $13.50
- AUPH $5.20
- 52 Week High
- PLSE $25.00
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- PLSE 51.51
- AUPH 63.15
- Support Level
- PLSE $15.50
- AUPH $8.73
- Resistance Level
- PLSE $17.27
- AUPH $9.10
- Average True Range (ATR)
- PLSE 0.75
- AUPH 0.44
- MACD
- PLSE 0.16
- AUPH 0.13
- Stochastic Oscillator
- PLSE 55.41
- AUPH 92.56
About PLSE Pulse Biosciences Inc (DE)
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.